You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy
SBC: MICROBIOTIX, INC. Topic: NIAIDHuman respiratory syncytial virus hRSV and human metapneumovirus hMPV are non segmented negative strand viruses NNSV and are the leading causes of acute respiratory tract infections in infants worldwide In addition hRSV is a significant cause of disease in elderly populations and can often be fatal for patients with compromised immune systems Currently no vaccines are available and exis ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
T SS needle protein inhibitors for the treatment of P aeruginosa infection
SBC: MICROBIOTIX, INC. Topic: NIAIDDESCRIPTION provided by applicant The inability to treat many Gram negative bacterial infections effectively with existing antibiotics is a major medical crisis Pseudomonas aeruginosa is a prime example of clinical isolates from critically ill patients are resistant to three or more drugs The overall goal of this project is to address the critical medical need by a novel approach of iden ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens
SBC: SILVER LAKE RESEARCH CORPORATION Topic: NIAIDPROJECT SUMMARY ABSTRACT This proposal describes Phase II of the development of a rapid immunoassay test kit for the determination oflactam antibiotic resistanceto be used as a point of care diagnostic test for urinary tract infectionsTodayantibiotics for UTI are prescribed empiricallywith no diagnostics available to clinicians to avoid treating resistant infections with the very drug to which the ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Intra procedure Deformable Ultrasound MRI Fusion for Prostate Biopsies
SBC: ZMK Medical Technologies, Inc. Topic: 102This Phase II proposal is a continuation of our successful Phase I grant whose overarching goal is to develop a more robust and accurate method for the deformable fusion of pre operative magnetic resonance images MRI and intra procedure trans rectal ultrasound TRUS images to guide prostate biopsy Prostate cancer is a major cause of death in the U S and biopsy is the gold standard for its dia ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Skin Sympathetic Nerve Activity and Cardiac Arrhythmias
SBC: ARRHYTHMOTECH Topic: NIDADESCRIPTION provided by applicant The objective of this Phase II STTR grant application is to continue the R Randamp D efforts initiated in Phase I The long term objective for Arrhythmotech is to develop and market an instrument for the simultaneous recording of sympathetic nerve activity SNA and electrocardiogram ECG using electrodes on the skin This method neuECG was discovered in Dr ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
SBC: FasCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing Therapeutics That Target RAD To Treat Leukemia and Lymphoma
SBC: Cyteir Therapeutics, Inc. Topic: NCIDESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of An Integrated High Throughput Imaging and Image Analysis Platform for Muscle
SBC: CytoInformatics LLC Topic: NIADESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Peptide Based Therapy for Lung Fibrosis
SBC: Novici Biotech LLC Topic: NHLBIDESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Real Time Oxygen Monitoring for Tissue Health Peripheral Artery Disease Application
SBC: PROFUSA, INC. Topic: NHLBIDESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health